TLSI Form 4: Chief Regulatory Officer gets new RSUs and options

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its Chief Regulatory Officer on a Form 4. On November 24, 2025, the officer received 50,000 restricted stock units payable in common stock at a price of $0, with the award vesting in four equal annual installments starting November 24, 2025, subject to continued employment. The filing also discloses an employee stock option to purchase 100,000 shares of common stock at an exercise price of $5.55 per share, with one-fourth vesting on the one-year anniversary of November 24, 2025 and the remainder vesting monthly over three years, also conditioned on continued employment.

After these transactions, the officer beneficially owns 127,640 shares of common stock directly and 323,782 derivative securities, reflecting equity-based incentives tied to future service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stevens Jennifer

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER CO 80031

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		A		50,000(1)	A	$0	127,640	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.55	11/24/2025		A		100,000		(2)	11/23/2035	Common Stock	100,000	$0	323,782	D

Explanation of Responses:

1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on November 24, 2025, subject to continued employment through the respective vesting date.

2. One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to continued employment through the respective vesting date.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards were reported in this TriSalus Life Sciences (TLSI) Form 4?

The Form 4 reports a grant of 50,000 restricted stock units payable in common stock at $0 and an employee stock option for 100,000 shares of common stock at an exercise price of $5.55 per share.

Who received the equity awards disclosed by TriSalus Life Sciences (TLSI)?

The equity awards were granted to an officer of TriSalus Life Sciences serving as Chief Regulatory Officer, as indicated in the relationship section of the filing.

How do the 50,000 restricted stock units for TLSI vest?

The 50,000 restricted stock units vest in four equal annual installments starting on November 24, 2025, with each installment requiring continued employment through the applicable vesting date.

What is the vesting schedule for the 100,000 TLSI stock options?

For the 100,000 stock options, one-fourth of the shares vest on the one-year anniversary of the vesting commencement date of November 24, 2025, and 1/36th of the remaining shares vest each month thereafter on the same calendar day, subject to continued employment.

What is the exercise price and expiration date of the TLSI stock options?

The employee stock option has an exercise price of $5.55 per share and an expiration date of November 23, 2035, with 100,000 shares of common stock underlying the option.

How many TLSI securities does the officer beneficially own after these grants?

Following the reported transactions, the officer beneficially owns 127,640 shares of common stock directly and 323,782 derivative securities, as shown in the ownership tables.

Was the TLSI transaction potentially made under a Rule 10b5-1 plan?

The form includes a checkbox to indicate if a transaction was made under a Rule 10b5-1(c) trading plan intended to satisfy affirmative defense conditions, although the excerpt does not show that box marked.